Skip to main content

Ranking Vaccines Applications of a Prioritization Software Tool: Phase III: Use Case Studies and Data Framework (2015) / Chapter Skim
Currently Skimming:

1 Introduction: SMART Vaccines and Smart Priorities
Pages 11-18

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 11...
... These health gains continue over generations to have a direct bearing on workforce productivity gains and the economic progress of nations. Moreover, scaling up of vaccination has been acknowledged as one of the most important mechanisms to help reduce the health achievement gaps between the developed and developing countries by 2035 -- a goal referred to as the "grand convergence" (Jamison et al., 2013)
Read the entire page →
From page 12...
... . Multi-attribute utility theory offers a strong axiomatic base for evaluating vaccines beyond a single criterion such as the standard infant mortality equivalents (or in modern terms, life-years saved)
Read the entire page →
From page 13...
... The second, modern approach began in the 1980s, when new technologies enabled advances in vaccine development that would not have been possible using the ­ mpirical approach. e NOTE: Closed boxes indicate licensed vaccines or vaccination practices that are already used.
Read the entire page →
From page 14...
... , the Phase II committee described the extensive testing it performed on the model using three additional vaccine candidates -- for human papillomavirus, rotavirus, and pneumococcal infections -- as it pursued the development of a functional prototype SMART Vaccines 1.0 in a Matlab environment that is executable in a Windows environment. Project Process and Stakeholders' Feedback In fall 2013, following the release of the Phase II products, a nine-member committee was appointed by the Institute of Medicine and the National Academy of Engineering to carry out the Phase III project.
Read the entire page →
From page 15...
... to a wide range of stakeholders at various meetings of major professional societies, federal advisory committees, and vaccine manufacturers and their consortiums. Additionally, the committee organized a public meeting to gather feedback from other stakeholder leaders for use in refining SMART Vaccines.
Read the entire page →
From page 16...
... and also with non­ overnment organizations, including civil society and ­ usiness g b organizations, and with other countries and international organizations, such as the World Health Organization, to share knowledge, expertise, and e ­ xperiences. The New York State Department of Health (NYSDOH)
Read the entire page →
From page 17...
... A consultant to the committee from Microsoft Corporation led the usability studies with these three user groups and prepared an independent report containing suggestions for improving SMART Vaccines (see Appendix A)
Read the entire page →

Key Terms

  • vaccine development
  • prioritization software
  • software tool
  • national vaccine
  • vaccine prioritization

  • vaccine program
  • utility theory
  • phase iii
  • health agency
  • serum institute

  • data synthesis
  • demonstrated smart
  • employing smart
  • prioritization model
  • vaccine plan

  • refining smart
  • rabies vaccine
  • prototype smart
  • additional vaccine
  • improving smart

  • vaccine manufacturers
  • engineer vaccine
  • potential host
  • indicate licensed
  • cost versus

  • committee organized
  • strong axiomatic
  • iii committee
  • vaccines beyond
  • gather feedback


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.